P1150: REAL WORLD DATA ON BORTEZOMIB-BASED THERAPY IN WALDENSTRÖM’S MACROGLOBULINAEMIA: EFFECTIVE EVEN IN MULTIPLY TREATED PATIENTS INCLUDING PRIOR BTK-INHIBITORS

por Uppal, E., Khwaja, J., Rismani, A., Kyriakou, C., D’Sa, S.
Publicado 2022

Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development

por Forde, K., Cocks, K., Wells, J. R., McMillan, I., Kyriakou, C.
Publicado 2023

P1112: TREATING BING-NEEL SYNDROME USING A TAILORED APPROACH: EXPERIENCE OF A SPECIALIST NEUROHAEMATOLOGY CLINIC

por Khwaja, J., Smyth, D., Rismani, A., Hoskote, C., Kyriakou, C., Lunn, M. P., D’Sa, S.
Publicado 2022

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

por Leleu, X, Kyriakou, C, Vande Broek, I, Murphy, P, Bacon, P, Lewis, P, Gilet, H, Arnould, B, Petrucci, M T
Publicado 2017

P1149: THE EVOLVING STATE OF PLAY IN 1000 PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINAEMIA IN THE UNITED KINGDOM (UK): A REAL-WORLD DATA ANALYSIS FROM THE WMUK RORY MORRISON REGISTRY...

por Uppal, E., Otamas, A., Khwaja, J., McCarthy, H., Kothari, J., Rismani, A., El-Sharkawi, D., Kyriakou, C., D’Sa, S.
Publicado 2022

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS

por Khwaja, J., Bomsztyk, J., Mahmood, S., Wisniowski, B., Shah, R., Tailor, A., Yong, K., Popat, R., Rabin, N., Kyriakou, C., Sive, J., Worthington, S., Hart, A., Dowling, E., Correia, N., Bygrave, C., Rydzewski, A., Jamroziak, K., Wechalekar, A.
Publicado 2022